JP2020512361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512361A5 JP2020512361A5 JP2019553224A JP2019553224A JP2020512361A5 JP 2020512361 A5 JP2020512361 A5 JP 2020512361A5 JP 2019553224 A JP2019553224 A JP 2019553224A JP 2019553224 A JP2019553224 A JP 2019553224A JP 2020512361 A5 JP2020512361 A5 JP 2020512361A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- complex
- molecule
- combination
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480339P | 2017-03-31 | 2017-03-31 | |
| US62/480,339 | 2017-03-31 | ||
| US15/937,493 US20190048055A1 (en) | 2017-03-31 | 2018-03-27 | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
| US15/937,493 | 2018-03-27 | ||
| PCT/US2018/025366 WO2018183821A1 (en) | 2017-03-31 | 2018-03-30 | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512361A JP2020512361A (ja) | 2020-04-23 |
| JP2020512361A5 true JP2020512361A5 (https=) | 2021-04-30 |
Family
ID=63678335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553224A Pending JP2020512361A (ja) | 2017-03-31 | 2018-03-30 | 癌治療のために抗ｃｄ３８抗体と併用したａｌｔ−８０３ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190048055A1 (https=) |
| EP (1) | EP3601363B1 (https=) |
| JP (1) | JP2020512361A (https=) |
| KR (1) | KR102748188B1 (https=) |
| CN (1) | CN110494449B (https=) |
| AU (1) | AU2018243550B2 (https=) |
| CA (1) | CA3058427C (https=) |
| TW (1) | TW201841651A (https=) |
| WO (1) | WO2018183821A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017271593B2 (en) | 2016-05-27 | 2021-04-22 | Altor Bioscience Corporation | Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN117986384A (zh) | 2017-03-06 | 2024-05-07 | 艾尔特生物科技公司 | 与il-12和il-18的基于il-15的融合物 |
| JP2023502712A (ja) * | 2019-11-21 | 2023-01-25 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法 |
| KR102692667B1 (ko) | 2020-11-17 | 2024-08-06 | 고려대학교 산학협력단 | 면역치료요법의 효능, 예후, 또는 내성 예측을 위한 바이오마커, 및 면역치료요법의 효능 증진을 위한 표적으로서 tctp의 용도 |
| CN113293191A (zh) * | 2021-05-28 | 2021-08-24 | 山东大学齐鲁医院 | Gfp转染肿瘤细胞的方法在检测肿瘤相关巨噬细胞吞噬功能中的应用 |
| WO2023178253A2 (en) * | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
| GB202315149D0 (en) | 2023-10-03 | 2023-11-15 | Celleron Therapeutics Ltd | Combination therapy |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507A (en) | 1851-11-11 | petess | ||
| US222A (en) | 1837-06-10 | Truss for the retention and radical cure qe hernia | ||
| US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| WO1994004689A1 (en) | 1992-08-14 | 1994-03-03 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant toxin with increased half-life |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7213961B2 (en) | 2003-07-11 | 2007-05-08 | Hubbell Incorporated | Low voltage luminaire assembly |
| US8772451B2 (en) | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| CN107880136B (zh) * | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| NZ630790A (en) * | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| CA3151221C (en) * | 2014-06-30 | 2026-01-13 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| AU2016333873A1 (en) * | 2015-10-06 | 2018-05-17 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treatment of metastatic and refractory cancers and tumors |
-
2018
- 2018-03-27 US US15/937,493 patent/US20190048055A1/en not_active Abandoned
- 2018-03-30 WO PCT/US2018/025366 patent/WO2018183821A1/en not_active Ceased
- 2018-03-30 CA CA3058427A patent/CA3058427C/en active Active
- 2018-03-30 CN CN201880022531.7A patent/CN110494449B/zh active Active
- 2018-03-30 KR KR1020197032255A patent/KR102748188B1/ko active Active
- 2018-03-30 EP EP18776459.2A patent/EP3601363B1/en active Active
- 2018-03-30 AU AU2018243550A patent/AU2018243550B2/en active Active
- 2018-03-30 JP JP2019553224A patent/JP2020512361A/ja active Pending
- 2018-03-31 TW TW107111499A patent/TW201841651A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512361A5 (https=) | ||
| EP2944323B1 (en) | Agents for treating tumours, use and method thereof | |
| JP2019515888A5 (https=) | ||
| JP2019516748A5 (https=) | ||
| JP2021525735A5 (https=) | ||
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| JP2021535149A5 (https=) | ||
| US20200377596A1 (en) | Dosing of bispecific t cell engager | |
| EP3972609B1 (en) | Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release | |
| JP2020510011A5 (https=) | ||
| JPWO2020043683A5 (https=) | ||
| CN102935228B (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| EP4319815A1 (en) | Dosing of bispecific t cell engager | |
| JP2013543869A5 (https=) | ||
| Sylvan et al. | Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression. | |
| JP7098518B2 (ja) | 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用 | |
| Chen et al. | IMMU-23. Eliminating Monocyte Chemoattraction Invokes Compensatory Neutrophil Influx and Proneural to Mesenchymal Transition in Glioblastoma | |
| Zhang et al. | PF299 EARLY RESPONSE OBSERVATION OF PEDIATRIC PATIENTS WITH BURKITT'S LYMPHOMA TREATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS | |
| Sun et al. | Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma | |
| US20150342925A1 (en) | Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress | |
| Zent | Monoclonal antibody therapy in chronic lymphocytic leukemia | |
| TW202517679A (zh) | 以抗ｉｌｔ２抗體治療癌症 | |
| JPWO2021108926A5 (https=) | ||
| Wendtner | Combination treatment for metastatic breast cancer | |
| JP2012254994A (ja) | 癌治療のための抗体およびグルココルチコイドの組み合わせ |